GW Pharmaceuticals cannabis drug gets regulatory OK in Australia
GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in…
News September 24GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in…
News September 24United Kingdom-based GW Pharmaceuticals posted marginal revenue growth in the second quarter over the previous quarter, citing challenges…
News August 7CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to treat seizures associated with a…
News August 3The United Kingdom has down-scheduled Epidyolex to the lowest level of control for drugs, greatly easing restrictions on…
News June 24Multistate marijuana operator iAnthus defaulted on interest payments, in part blaming the coronavirus. In addition, the New York-based…
News April 11Epidiolex, the only plant-derived cannabis drug approved by the U.S. Food and Drug Administration, is no longer considered…
News April 7The only medical cannabis product in the Australian Register of Therapeutic Goods might soon be joined by another.
News January 30A popular cannabis-derived epilepsy treatment is increasing sales for a London company making pharmaceutical treatments from marijuana.
News January 13New British guidelines for the first time recommend that two plant-based cannabis medicines – Sativex and Epidiolex –…
News November 12